Advertisement

Topics

Latest "Morgan Properties" News Stories

17:07 EDT 24th April 2018 | BioPortfolio

Here are the most relevant search results for "Morgan Properties" found in our extensive news archives from over 250 global news sources.

More Information about Morgan Properties on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Morgan Properties for you to read. Along with our medical data and news we also list Morgan Properties Clinical Trials, which are updated daily. BioPortfolio also has a large database of Morgan Properties Companies for you to search.

Showing "Morgan Properties" News Articles 1–25 of 2,200+

Tuesday 24th April 2018

NatureWorks Names Richard Altice New President and CEO

Altice joins company as it continues market-leading growth and innovation. NatureWorks’ board of directors named Richard Altice as the company’s new President and Chief Executive Officer, replacing Marc Verbruggen, who led the company from 2008 to his retirement in 2017. Altice comes to NatureWorks from PolyOne Corporation where he ...


Connect Biopharmaceuticals Advances CBP-201, a Novel Monoclonal Antibody Against IL-4Rα, Into Clinical Development

TAICANG, China, April 24, 2018 /PRNewswire/ -- Connect Biopharmaceuticals, Ltd. today announced that it has submitted an application in Australia to begin a phase 1 clinical trial to evaluate CBP-201, the company's monoclonal antibody candidate for allergic inflammation. The planned phase 1 clinical trial is a randomized, double-blind, placebo-controlled study in healthy subjects to evaluate the ...

EY Announces Geoff Gross of Medical Guardian Entrepreneur Of The Year 2018 Award Finalist in Greater Philadelphia

EY announced that Geoff Gross, Founder & CEO of Medical Guardian, a leading provider of innovative medical alert systems, is a finalist for the Entrepreneur Of The Year® 2018 Award in the Greater Philadelphia region. This is the fourth year in a row Geoff has been named a finalist of EY’s Entrepreneur of the Year Award. “I’m honored to ...


Simulations Plus Announces Employee Bonuses

Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development, today announced that it will be distributing a one-time $1,000 discretionary cash bonus to each of its employees. Walt Woltosz, chairman and chief executive officer of Si...

Gateway for Cancer Research Announces Completion of Phase I Clinical Trial Using “Tumor Paint” in Pediatric Brain Cancer Surgery

Dr. Sarah Leary, pediatric oncologist at Seattle Children’s Hospital, completes trial of Tumor Paint BLZ-100 in 28 children undergoing brain tumor removal surgery Gateway for Cancer Research (Gateway), a non-profit dedicated to funding transformational cancer research, announces the completion of a Phase I clinical project led by Dr. Sarah ...

Cosmeist Launching Amino Mason Line of Hair Care Products Packed With Amino Acids and Forest Botanicals in U.S. Marketplace

Cosmeist is preparing to launch both its Moist and Smooth Amino Mason lines of rose-scented hair care products, each packed with amino acids and forest botanicals carefully selected to create silky smooth, luminous hair, into the U.S. marketplace. BOCA RATON, Fla. (PRWEB) April 24, 2018 Cosmeist is preparing to launch both its Moist and Smooth Amino Mason lines of rose-scented hair care products,...

Monday 23rd April 2018

New compound could offer pain-relieving properties without risk of addiction

Researchers at the University of Michigan have engineered a new compound that animal tests suggest could offer the pain-relieving properties of opioids such as morphine and oxycodone without the risk of addiction.

Studies show hemp's potential for treating ovarian cancer

Results from some of the first studies to examine hemp's ability to fight cancer show that it might one day be useful as plant-based treatment for ovarian cancer. Hemp is part of the same cannabis family as marijuana but doesn't have any psychoactive properties or cause addiction.

Goldman Sachs stellt Experten für Kryptowährungen ein: Bank-Chef Lloyd Blankfein will seine Kunden beim ...

Bank-Chef Lloyd Blankfein will seine Kunden beim Handel mit Bitcoin und Co. unterstützen. Damit grenzt er sich klar von JP-Morgan-Chef Dimon ab.Lloyd Blankfein hat sich von Anfang an alle Türen off...

MorphoSys Announces Closing of Nasdaq IPO through an ADS Offering and Exercise of the Underwriters' Option to Purchase Additional ADSs, Leading to Total Gross Proceeds of USD 239 million (news with additional features)

DGAP-News: MorphoSys AG / Key word(s): Corporate Action/IPO 23.04.2018 / 22:05 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, April 23, 2018 MorphoSys Announces Closing of Nasdaq IPO through an ADS Offering and Exercise of the Underwriters' Option to Purchase Additional ADSs, Leading to Total Gross Proceeds of USD 239 million MorphoSys ...

Ranexa API Insight,2018 [Report Updated: 14022018] Prices from USD $500

IntroductionDelveInsight's, Ranexa API Insight, 2018 report provides product and API manufacturers' details across the globe along with the location. The report gives the clear idea on the country wise DMF filed by worldwide companies related to Ranexa . The report also highlights the patent details of Ranexa . MethodologyThe report is built using data and information sourced from proprietary da...

Promise for safer opioid pain reliever

Researchers have engineered a new compound that animal tests suggest could offer the pain-relieving properties of opioids such as morphine and oxycodone without the risk of addiction.

Apple-Aktie: Kursschwächen nach Quartalsbericht ausnutzen!

New York - Apple-Aktienanalyse von Analystin Katy Huberty von Morgan Stanley: Analystin Katy Huberty von Morgan Stanley bestätigt im Rahmen einer Aktienanalyse ihre Übergewichten-Empfehlung für die...

EY Announces Dawn Zier, CEO of Nutrisystem, Inc., Entrepreneur Of The Year® 2018 Award Finalist in Greater Philadelphia

EY has announced that Dawn Zier, CEO of Nutrisystem, Inc. (NASDAQ: NTRI), a leading provider of weight management products and services including Nutrisystem® and South Beach Diet® brands, is a finalist for the Entrepreneur Of The Year® 2018 Award in the Greater Philadelphia Region. The awards program recognizes entrepreneurs who are excelling in areas ...

Kaleido Biosciences Announces Appointment of Joshua Brumm as Chief Financial Officer

Kaleido Biosciences, a clinical-stage biotechnology company developing novel chemistries to unlock the power of the human microbiome, today announced the appointment of Joshua Brumm as chief financial officer. Mr. Brumm, an accomplished CFO with extensive financial and operational experience, will report directly to chief executive officer and chair, Micha...

CBT Pharmaceuticals and CrystalGenomics Announce Partnership for Co-development of Global Immuno-Oncology Therapy

CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies, and CrystalGenomics, Inc., (KOSDAQ:083790), a Korea-based biopharmaceutical company with drug discovery, development and commercialization capabilities, today announced ...

Annual Report 2017 Active Biotech AB (publ)

    PRESS RELEASE Active Biotech's Annual Report 2017 is now available för download at www.activebiotech.com. The Annual Report will only be digitally distributed. The English version will be available within short. Lund, April 23, 2018 Active Biotech AB (publ) Helén TuvessonCEO For further information, please contact:Hans Kolam, CFOTel. +46 (0)46 192044 About ...

Wood properties improved for biofuel production

Scientists at the Forest Biotechnology Group at North Carolina State University can now predict the results from modifying 21 -More- 

EpimAb Biotherapeutics and Zhejiang Teruisi Biopharmaceutical Announce Development Collaboration on Epimab’s FIT012 Bispecific Antibody Program

Zhejiang Teruisi Biopharmaceutical to take the lead in developing the program in China, Epimab retains worldwide commercial rights outside of China EpimAb Biotherapeutics, a Shanghai-based biopharmaceutical company specializing in bispecific antibodies, and Zhejiang Teruisi Biopharmaceutical, a company specialized in the development of biologics...

Vivanza API Insight,2018 [Report Updated: 14022018] Prices from USD $500

IntroductionDelveInsight's, Vivanza API Insight, 2018 report provides product and API manufacturers' details across the globe along with the location. The report gives the clear idea on the country wise DMF filed by worldwide companies related to Vivanza . The report also highlights the patent details of Vivanza . MethodologyThe report is built using data and information sourced from proprietary...

Sunday 22nd April 2018

Sensipar API Insight,2018 [Report Updated: 14022018] Prices from USD $500

IntroductionDelveInsight's, Sensipar API Insight, 2018 report provides product and API manufacturers' details across the globe along with the location. The report gives the clear idea on the country wise DMF filed by worldwide companies related to Sensipar . The report also highlights the patent details of Sensipar . MethodologyThe report is built using data and information sourced from propriet...

Hemp shows potential for treating ovarian cancer

(Experimental Biology 2018) Results from some of the first studies to examine hemp's ability to fight cancer show that it might one day be useful as plant-based treatment for ovarian cancer. Hemp is part of the same cannabis family as marijuana but doesn't have any psychoactive properties or cause addiction.

Baraklyud API Insight,2018 [Report Updated: 14022018] Prices from USD $500

IntroductionDelveInsight's, Baraklyud API Insight, 2018 report provides product and API manufacturers' details across the globe along with the location. The report gives the clear idea on the country wise DMF filed by worldwide companies related to Baraklyud . The report also highlights the patent details of Baraklyud . MethodologyThe report is built using data and information sourced from propr...

Abemaciclib Launch Insight, 2018 [Report Updated: 14022018] Prices from USD $1500

DelveInsight's, Abemaciclib, Launch Insight, 2018 report provides comprehensive Insight about the Abemaciclib's launch. The report covers all the indications for which the Abemaciclib is being developed and also provides the competitive landscape for the major indications. The report further includes patent details, forecasted sales till 2022 and post launch market positioning. The report will pro...

Saturday 21st April 2018

Ovensa Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 14032018] Prices from USD $250

SummaryOvensa Inc Ovensa is a preclinical stage company that develops nanotherapeutics. The company uses its proprietary Triozan nanomedicine delivery platform that has mucosal and brainbarrier crossing properties used in treatment of oncology and neurodegenerative diseases. Its Triozan helps in the efficient delivery of a wide range of drugs across multiple barriers such as blood brain barrier, b...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks